19 Blackstone Street
About Lysosomal TherapeuticsLysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
Founders: Dimitri Krainc, Joseph Mazzulli, Henri Termeer, Peter Wirthand, Peter Wirth, Bob Carpenter, and Kees Been
Founder and CEO: Kees Been
CFO: Daniel Geffken
CSO: Peter Lansbury
2 articles with Lysosomal Therapeutics
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
Allergan Enters Parkinson's Disease Through Option Arrangement With Lysosomal Therapeutics For Its Potential First-In-Class Breakthrough Compounds